Search

Your search keyword '"Temprano G"' showing total 7 results
Start Over Author "Temprano G"
7 results on '"Temprano G"'

1. Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations

Author

Temprano-Sagrera, G, Sitlani, CM, Bone, WP, Martin-Bornez, M, Voight, BF, Morrison, AC, Damrauer, SM, de Vries, PS, Smith, NL, Sabater-Lleal, M, Krupinksi, J, Dehghan, A, Heath, AS, Reiner, AP, Johnson, A, Richmond, A, Peters, A, van Hylckama Vlieg, A, McKnight, B, Psaty, BM, Hayward, C, Ward-Caviness, C, O’Donnell, C, Chasman, D, Strachan, DP, Tregouet, DA, Mook-Kanamori, D, Gill, D, Thibord, F, Asselbergs, FW, Leebeek, FWG, Rosendaal, FR, Davies, G, Homuth, G, Temprano, G, Campbell, H, Taylor, HA, Bressler, J, Huffman, JE, Rotter, JI, Yao, J, Wilson, JF, Bis, JC, Hahn, JM, Desch, KC, Wiggins, KL, Raffield, LM, Bielak, LF, Yanek, LR, Kleber, ME, Mueller, M, Kavousi, M, Mangino, M, Liu, M, Brown, MR, Conomos, MP, Jhun, MA, Chen, MH, de Maat, MPM, Pankratz, N, Peyser, PA, Elliot, P, Wei, P, Wild, PS, Morange, PE, van der Harst, P, Yang, Q, Le, NQ, Marioni, R, Li, R, Cox, SR, Trompet, S, Felix, SB, Völker, U, Tang, W, Koenig, W, Jukema, JW, Guo, X, Lindstrom, S, Wang, L, Smith, EN, Gordon, W, de Andrade, M, Brody, JA, Pattee, JW, Haessler, J, Brumpton, BM, Chasman, DI, Suchon, P, Turman, C, Germain, M, MacDonald, J, Braekkan, SK, Armasu, SM, Temprano-Sagrera, G, Sitlani, CM, Bone, WP, Martin-Bornez, M, Voight, BF, Morrison, AC, Damrauer, SM, de Vries, PS, Smith, NL, Sabater-Lleal, M, Krupinksi, J, Dehghan, A, Heath, AS, Reiner, AP, Johnson, A, Richmond, A, Peters, A, van Hylckama Vlieg, A, McKnight, B, Psaty, BM, Hayward, C, Ward-Caviness, C, O’Donnell, C, Chasman, D, Strachan, DP, Tregouet, DA, Mook-Kanamori, D, Gill, D, Thibord, F, Asselbergs, FW, Leebeek, FWG, Rosendaal, FR, Davies, G, Homuth, G, Temprano, G, Campbell, H, Taylor, HA, Bressler, J, Huffman, JE, Rotter, JI, Yao, J, Wilson, JF, Bis, JC, Hahn, JM, Desch, KC, Wiggins, KL, Raffield, LM, Bielak, LF, Yanek, LR, Kleber, ME, Mueller, M, Kavousi, M, Mangino, M, Liu, M, Brown, MR, Conomos, MP, Jhun, MA, Chen, MH, de Maat, MPM, Pankratz, N, Peyser, PA, Elliot, P, Wei, P, Wild, PS, Morange, PE, van der Harst, P, Yang, Q, Le, NQ, Marioni, R, Li, R, Cox, SR, Trompet, S, Felix, SB, Völker, U, Tang, W, Koenig, W, Jukema, JW, Guo, X, Lindstrom, S, Wang, L, Smith, EN, Gordon, W, de Andrade, M, Brody, JA, Pattee, JW, Haessler, J, Brumpton, BM, Chasman, DI, Suchon, P, Turman, C, Germain, M, MacDonald, J, Braekkan, SK, and Armasu, SM

Abstract

Background: Multi-phenotype analysis of genetically correlated phenotypes can increase the statistical power to detect loci associated with multiple traits, leading to the discovery of novel loci. This is the first study to date to comprehensively analyze the shared genetic effects within different hemostatic traits, and between these and their associated disease outcomes. Objectives: To discover novel genetic associations by combining summary data of correlated hemostatic traits and disease events. Methods: Summary statistics from genome wide-association studies (GWAS) from seven hemostatic traits (factor VII [FVII], factor VIII [FVIII], von Willebrand factor [VWF] factor XI [FXI], fibrinogen, tissue plasminogen activator [tPA], plasminogen activator inhibitor 1 [PAI-1]) and three major cardiovascular (CV) events (venous thromboembolism [VTE], coronary artery disease [CAD], ischemic stroke [IS]), were combined in 27 multi-trait combinations using metaUSAT. Genetic correlations between phenotypes were calculated using Linkage Disequilibrium Score Regression (LDSC). Newly associated loci were investigated for colocalization. We considered a significance threshold of 1.85 × 10−9 obtained after applying Bonferroni correction for the number of multi-trait combinations performed (n = 27). Results: Across the 27 multi-trait analyses, we found 4 novel pleiotropic loci (XXYLT1, KNG1, SUGP1/MAU2, TBL2/MLXIPL) that were not significant in the original individual datasets, were not described in previous GWAS for the individual traits, and that presented a common associated variant between the studied phenotypes. Conclusions: The discovery of four novel loci contributes to the understanding of the relationship between hemostasis and CV events and elucidate common genetic factors between these traits.

Published
2022

2. Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus (vol 13, 1222, 2022)

Author

Stacey, D, Chen, LY, Stanczyk, PJ, Howson, JMM, Mason, AM, Burgess, S, MacDonald, S, Langdown, J, McKinney, H, Downes, K, Farahi, N, Peters, JE, Basu, S, Pankow, JS, Tang, WH, Pankratz, N, Sabater-Lleal, M, de Vries, PS, Smith, NL, Dehghan, A, Heath, AS, Morrison, AC, Reiner, AP, Johnson, A, Richmond, A, Peters, A, Vlieg, AV, McKnight, B, Psaty, BM, Hayward, C, Ward-Caviness, C, O'Donnell, C, Chasman, D, Strachan, DP, Tregouet, DA, Mook-Kanamori, D, Gill, D, Thibord, F, Asselbergs, FW, Leebeek, FWG, Rosendaal, FR, Davies, G, Homuth, G, Temprano, G, Campbell, H, Taylor, HA, Bressler, J, Huffman, JE, Rotter, JI, Yao, J, Wilson, JF, Bis, JC, Hahn, JM, Desch, KC, Wiggins, KL, Raffield, LM, Bielak, LF, Yanek, LR, Kleber, ME, Mueller, M, Kavousi, M, Mangino, M, Conomos, MP, Liu, ML, Brown, MR, Jhun, MA, Chen, MH, de Maat, MPM, Peyser, PA, Elliot, P, Wei, P, Wild, PS, Morange, PE, van der Harst, P, Yang, Q, Le, NQ, Marioni, R, Li, RF, Damrauer, SM, Cox, SR, Trompet, S, Felix, SB, Volker, U, Koenig, W, Jukema, JW, Guo, XQ, Gelinas, AD, Schneider, DJ, Janjic, N, Samani, NJ, Ye, S, Summers, C, Chilvers, ER, Danesh, J, and Paul, DS

Published
2022

3. [Public production as a key factor for access to antivenoms in the Region of the Americas].

Author

Temprano G, Aprea P, and Dokmetjian JC

Subjects
Americas, Humans, Antivenins therapeutic use, Drug Industry, Health Services Accessibility
Abstract

Injuries caused by venomous animals affect vast areas of Latin America, Southern Asia, Southeast Asia, sub-Saharan Africa, and Oceania, and pose a serious problem for global public health. Based on an analysis of the current panorama of global production of ophidian and arachnid antivenoms, it is concluded that they are semi-orphaned products. This is a favorable scenario in which to strengthen public laboratory production. Governments should make a political decision in this regard in the interest of equity in population health. In the Region of the Americas, these actions could be part of a program led by the Pan American Health Organization to ensure the availability of these biologicals in strategically located health centers. Twelve public facilities producing antivenoms have been identified in the Region, including Brazil and Mexico, which are the biggest public producers. These laboratories should be managed like industrial operations that produce tangible goods without ignoring strategic planning. National regulatory authorities should help the public laboratories that produce them by providing necessary technical assistance and consultancy without any loss of impartiality or rigor in the evaluation of their quality management systems. New superior production technologies using hyperimmune mammalian plasma are in the experimental phase; no information on its production has been found in the literature.

Published
2017

4. Comparative study of airborne viable particles assessment methods in microbiological environmental monitoring.

Author

Temprano G, Garrido D, and Daquino M

Subjects
Analysis of Variance, Argentina, Environmental Monitoring instrumentation, Equipment Design methods, Time Factors, Air Microbiology, Environmental Monitoring methods, Particle Size
Abstract

A comparative study was done among available assessment methods to measure airborne viable particles in controlled rooms. Active methods were compared (sieve/nozzle impactor, slit-to-agar, centrifugal, filtration, and impinger). The comparative study was carried out by means of a two-way (factors: day and method) analysis of variance, after to logarithmical transformation of experimental results in order to fulfill the normality test of the variables. Statistically significant differences were found among the results of the five methods (P < 0.0001). In a post hoc study, by means of Tukey's test, no differences were found among centrifugal, filtration, and impinger methods. Differences were found among all the other methods (P < 0.05). It is concluded that centrifugal, filtration, and impinger methods (in which numerical results were higher than in the others) may be the most suitable methods for microbiological monitoring of a clean room. The mean results among the three selected active methods were compared with results on the settle plate (SP) (the passive method). A relationship was established between results of the passive method (CFU/h/plate 90 mmø) and the results of active methods (CFU/m3 air). By means of a lineal regression study, it was obtained a relation factor of 22.7; (95% CI: 19.7, 25.7). This factor is only valid for values between 3 and 16 in CFU/h/plate 90 mmø, and it is put on record that the experimental study took place in a room that fulfills Class D clean room specifications (WHO standards) in microbiological terms.

Published
2004

5. What is the scope of bioluminiscence in pharmaceutical clean rooms monitoring?

Author

Temprano GC and D'Aquino M

Subjects
Bacteria chemistry, Drug Industry, Escherichia coli chemistry, Staphylococcus aureus chemistry, Environment, Controlled, Environmental Monitoring methods, Luminescent Measurements
Abstract

By means of bioluminiscence ATP present in a sample can be quantified. Thus, it would be a method able to evaluate microbiological or organic matter (from vegetal or animal origin) contamination. The present work analyzes the possibility to assess--from the microbiological point of view--the air of pharmaceutical clean rooms by means of bioluminiscence, using the luminomiter HY-LITE 2 [Merck]. It is thought that the use of this methodology versus microbiological classical methods, will allow to obtain results in the working day. Classical methods demand a minimum of 72 hs incubation to read results. But the real conclusion is that with the used technology, it is not possible to evaluate microbiologically the air of pharmaceutical clean rooms.

Published
2003

6. [Changes in the norms governing practices for the manufacture of pharmaceutical products: implications for the MERCOSUR].

Author

Temprano G, Prats S, and Bregni C

Subjects
Europe, European Union, Drug Compounding standards, Drug Industry standards
Abstract

It is done a comparative study between the "Recommended rules for drug products manufacturing and inspection", approved in 1975 by the World Health Organization (and still in force in the MERCOSUR); and the standards published in 1992 by the WHO Expert Committee on Specifications for Pharmaceutical Preparations 32nd Report, named "Good Manufacturing Practices for pharmaceutical products". The correspondence between the regulation in force in the MERCOSUR and the Good Manufacturing Practices Inspection Guide for pharmaceutical industry, used by Health Authorities in the Common Market Member States, is analysed. It is noticed a disagreement between the rule in force and the instrument for verifying its fulfillment. The proposal of this article is the adoption by the Common Market Group, of the rules published by the WHO in 1992, and the establishment of an inspection guide which absolute agrees with it.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results